1. Introduction {#sec1-diagnostics-09-00212}
===============

A Modic change (MC) is a vertebral bone marrow change visible in magnetic resonance imaging (MRI). Three different types of MC have been described, of which Type 1 (M1) shows fibrovascular replacement of the bone marrow and represents an inflammatory lesion; Type 2 MC (M2) shows fatty replacement of the red bone marrow; and Type 3 MC (M3) demonstrates subchondral bone sclerosis \[[@B1-diagnostics-09-00212],[@B2-diagnostics-09-00212],[@B3-diagnostics-09-00212],[@B4-diagnostics-09-00212]\]. MC is associated with chronic low back pain (CLBP) \[[@B5-diagnostics-09-00212],[@B6-diagnostics-09-00212],[@B7-diagnostics-09-00212]\] and M1 shows a stronger association with CLBP than other MC types \[[@B8-diagnostics-09-00212],[@B9-diagnostics-09-00212],[@B10-diagnostics-09-00212]\]. In a Finnish patient study, conversion from M1 to M2 over two years was associated with improvement of pain symptoms \[[@B11-diagnostics-09-00212]\]. Similar findings have been obtained among Danish patients \[[@B12-diagnostics-09-00212]\].

Both infectious or autoimmune etiologies have been suggested as causes of MC, and both presuppose structural damage of the endplate \[[@B13-diagnostics-09-00212],[@B14-diagnostics-09-00212],[@B15-diagnostics-09-00212]\]. However, improved diagnostic tools are needed to detect early MC lesions. One novel pre-clinical technique that holds great clinical potential is nuclear magnetic resonance spectroscopy, which is a noninvasive method to quantify Cutibacterium (formerly Propionibacterium) acnes load on the intervertebral discs \[[@B16-diagnostics-09-00212],[@B17-diagnostics-09-00212]\]. There is also an urgent need to develop other MC biomarkers in order to increase early diagnosis and the choice of the right treatment and establishment of MC prognosis \[[@B13-diagnostics-09-00212]\].

A biomarker is defined as a characteristic that is objectively measured and evaluated as an indicator of normal biologic or pathogenic processes, or pharmacologic responses to a therapeutic intervention \[[@B18-diagnostics-09-00212]\]. Molecular diagnostic techniques have developed in recent years and may be helpful in revealing diseases at their early stage. However, only two studies of MC serum biomarkers have been published so far. In the first, serum high-sensitive C-reactive protein (hs-CRP) was higher among patients with M1 than among those with M2, or those without MC but with CLBP \[[@B19-diagnostics-09-00212]\]. Another small French case-control study in turn found no difference in bone mineral density and bone remodeling marker levels (serum C-terminal crosslinked type 1 telopeptide, procollagen type 1 N-terminal propeptide, osteocalcin, and bone-specific alkaline phosphatase) among chronic LBP patients with M1 or without MC \[[@B20-diagnostics-09-00212]\]. We have previously demonstrated how a single intravenous infusion of 5 mg zoledronic acid (ZA) decreased the intensity of pain among patients with CLBP in the short-term in comparison to placebo \[[@B21-diagnostics-09-00212]\]. We hypothesized that the beneficial effect of ZA on symptoms may be partly due to the reduction of inflammation, which in turn may be reflected by serum biomarkers related to inflammation and bone turnover. Therefore, the objective of our study was to compare the effect of a single intravenous infusion of 5 mg ZA to that of placebo infusion on the change in the serum biomarker profile of patients with MC, and to evaluate whether serum biomarkers correlate with the type and size of MC at baseline.

2. Materials and Methods {#sec2-diagnostics-09-00212}
========================

2.1. Study Design and Selection of Patients {#sec2dot1-diagnostics-09-00212}
-------------------------------------------

The study population consisted of patients with CLBP and MC in lumbar MRI \[[@B21-diagnostics-09-00212]\]. Inclusion criteria were LBP for at least three months, LBP intensity of at least six on the 10-cm Visual Analog Scale (VAS) or an Oswestry Disability Index (ODI) \[[@B22-diagnostics-09-00212]\] of at least 30% and an MC (M1, M2, or M1/2) in MRI \[[@B21-diagnostics-09-00212]\].

The Oulu University Hospital ethics committee approved the study protocol (121/2008, 18 August 2008). Informed consent was obtained from all participants (ClinicalTrials.gov NCT01330238).

2.2. Treatment Intervention {#sec2dot2-diagnostics-09-00212}
---------------------------

Patients were randomized into a ZA group with an infusion of 5 mg of ZA (*n* = 20) or a placebo group (saline infusion, *n* = 20). Before the administration of the infusion, all the patients received 600 mg of ibuprofen or 1 g of paracetamol orally to prevent potential acute phase reactions, and 100,000 units of Vitamin D (VigantolR) orally to avoid hypocalcemia \[[@B21-diagnostics-09-00212]\].

2.3. Magnetic Resonance Imaging {#sec2dot3-diagnostics-09-00212}
-------------------------------

The average interval between baseline imaging and infusion was four months (range 0.4 to 11.5 months). Follow-up imaging was performed on average 11.9 months (range 11 to 13 months) after infusion \[[@B23-diagnostics-09-00212]\]. The MRI equipment of the baseline imaging included five 1.5 T units (GE Signa Twinspeed, General Electric Medical Systems, Milwaukee, WI, USA; Philips Achieva and Philips Intera, Philips Medical Systems, Eindhoven, The Netherlands; Siemens Avanto and Siemens Espree, Siemens Medical, Erlangen, Germany), a 0.34 T unit (Siemens Magnetom C, Siemens Medical, Erlangen, Germany) and a 0.23 T unit (Philips Panorama, Philips Medical Systems, Eindhoven, The Netherlands). The imaging sequences were sagittal T1-weighted (T1 W) turbo spin-echo (TSE) or fast spin-echo (FSE) with fluid attenuation inversion recovery (FLAIR), sagittal T2-weighted (T2 W) TSE/FSE, and short tau inversion recovery sequences (STIR). The specific imaging parameters have been described previously \[[@B23-diagnostics-09-00212]\]. The MRI equipment of the one-year follow-up imaging included two 1.5 T units (GE Signa Twinspeed and GE Optima, General Electric Medical Systems, Milwaukee, WI, USA) and a 3 T unit (Siemens Skyra, Siemens Medical, Erlangen, Germany). Imaging protocols were established for clinical spine imaging.

2.4. Image Analysis {#sec2dot4-diagnostics-09-00212}
-------------------

We analyzed the MRIs for type and volume of each MC from sagittal images at a clinical workstation (Neaview Radiology, version 2.23, Neagen Corporation, Oulu, Finland) \[[@B23-diagnostics-09-00212]\]. MC type was assessed using T1 W and T2 W images as previously described \[[@B10-diagnostics-09-00212]\]. Four MC type groups were created: M1 (100%), predominating M1 (M1/2 (65:35%)), predominating M2 (M1/2 (35:65%)) and M2 (100%). The first two groups were considered M1-dominant, and the latter two M2-dominant. M1 was defined as consisting of purely oedemic signal changes and M2 consisting of purely fatty signal changes. Predominating M1 was defined as mixed Type 1/2 MC with more oedemic signal changes and predominating M2 as Type 1/2 MC with more fatty signal changes. The MC area (cm^2^) was determined from T2 W images. The volume (cm^3^) of each MC lesion was calculated by multiplying the area with the spacing.

2.5. Analysis of Serum Biomarkers {#sec2dot5-diagnostics-09-00212}
---------------------------------

Whole blood was drawn at noon from fasting patients using serum collection tubes prior to the intervention (baseline), at one-month and at one-year follow-up. We told all the participants not to exercise, eat, or drink the previous evening or the morning before the blood were to be taken. The blood samples were allowed to clot at room temperature for 30--60 min and then centrifuged at 2500× *g* for 10 min at 4 °C. The resulting serum supernatant was stored in aliquots, first at −20 °C, and were then transferred within 2--20 h to −70 °C. We took serum samples from 40 patients at three timepoints (*n* = 120) to assess the selected inflammatory and signaling molecules, growth factors and markers of bone turnover. We measured the serum concentrations of 50 biomarkers, and quantified 38 biomarkers using electro-chemiluminescent based multi-array immunoassays from MesoScale Discovery (MSD, Rockville, MD, USA), following the protocol of the manufacturer: Chemokine panel: Eotaxin, eotaxin-3, interferon-gamma-inducible protein (IP)-10, macrophage inflammatory protein (MIP)-1-alpha, MIP-1-beta, monocyte chemotactic protein (MCP)-1, MCP-4, macrophage-derived chemokine (MDC)-1, regulated on activation normal T-expressed and secreted (RANTES), thymus and activation regulated chemokine (TARC); Cytokine panel: Granulocyte--macrophage colony stimulating factor (GM-CSF), interleukin (IL)-5, interleukin (IL)-7, IL-12/23p40, IL-15, IL-16, IL-17A, tumor necrosis factor (TNF)-beta; Inflammation panel: Interferon (IFN)-gamma, IL-1-alpha, IL-1-beta, IL-2, IL-6, IL-8, IL-12p70, TNF-alpha, IL-4, IL-10, IL-13; Angiogenesis panel: Vascular endothelial growth factor (VEGF)-A, VEGF-C, VEGF-D, TEK receptor tyrosine kinase (Tie-2), fms related tyrosine kinase 1 (Flt-1), basic fibroblast growth factor (bFGF); and Vascular injury panel: Intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, serum amyloid A (SAA). To analyze the interleukin 1 receptor antagonist (IL-1RA), we used epidermal growth factor (EGF), hepatocyte growth factor(HGF), interferon-alpha (IFN-A), interleukin-2 receptor (IL-2R) and monokine induced by gamma-interferon (MIG-1), a Cytokine Human Magnetic Multi-Plex Panel (Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer's instructions. The receptor activator of NF-κB ligand (RANKL) was measured using a commercial Luminex single plex kit (Human RANKL single plex kit, MilliplexTM Map, Merck Millipore, Billerica, MA, USA), and soluble interleukin-1 receptor, type II (IL-1sRII) with a human IL-1RII Quantikine Elisa kit (R&D Systems, Minneapolis, MN, USA). All Luminex assays were performed using Luminex xMAP Technology (Bio-Plex 200 System; BioRad, Hercules, CA, USA). For the IL-1sRII Elisa assay, absorption was read at 450 nm using an ELISA plate absorbance reader, and the correction was made at 570 nm (Multiskan MS, Thermo Scientific, Vantaa, Finland). Plasma alkaline phosphatase activity (AFOS) was analyzed using the IFCC recommended enzymatic method (Advia, Siemens, Germany). Serum highly sensitive CRP (hs-CRP) was analyzed using a nephelometric instrument (BN ProSpec, Siemens, Germany). Intact procollagen I N-terminal propeptide(iPINP) and C telopeptide of type I collagen(CTX-I) analyses were performed using the IDS-iSYS Multi-Discipline Automated System (IDS, Bolton, UK). As the results of 11 biomarkers (EGF, GM-CSF, IL-1A, IL-1B, IL-1RA, IL-2, IL-4, IL-5, IL-10, IL-12p70, IL-13) were below the limit of quantification for more than half of the samples in the whole study, we excluded them from the final results.

2.6. Statistical Analyses {#sec2dot6-diagnostics-09-00212}
-------------------------

The background variables are presented as frequencies with proportions and means with standard deviations. We compared these variables of the ZA and placebo groups using the chi-square test or independent samples *t*-test, respectively. The serum biomarkers at baseline, one month and one year are separately presented as medians with interquartile range for the ZA and placebo groups. The change in serum biomarkers from baseline to one month and one year in the ZA and placebo groups, and in the M1- and M2-dominant MC were compared using Mann--Whitney's U-test. The change in the serum biomarkers from baseline to one month and one year in the ZA and placebo groups, and in the M1- and M2-dominant MC were compared separately, using the Wilcoxon signed-rank test. We analyzed the correlation of the change in serum biomarkers from baseline to one year with a change in primary MC total volume, M1 volume and M2 volume, and with a change in LBP using Spearman's rank correlation coefficient. The Benjamini--Hochberg (B--H) procedure, with a 10% false discovery rate, was used to correct for multiple comparisons. We used IBM SPSS Statistics, version 24.0 to conduct the analyses.

3. Results {#sec3-diagnostics-09-00212}
==========

3.1. Study Population {#sec3dot1-diagnostics-09-00212}
---------------------

All 40 enrolled, eligible patients participated in the one-year follow-up. There were no statistically significant differences between the baseline demographic characteristics of the ZA and placebo groups ([Table 1](#diagnostics-09-00212-t001){ref-type="table"}). The patients' mean age was 50 (SD 8.3) and mean body mass index (BMI) 26.8 (SD 3.2). The median duration of LBP was 330 (IQR 216-365) days and the mean VAS score for LBP was 6.7 (SD 1.5). The baseline serum biomarker concentrations of the placebo and ZA groups did not differ significantly.

The results of 11 biomarkers were below the limit of quantification for more than half of the samples in the whole study and were thus excluded from the final results. [Table 2](#diagnostics-09-00212-t002){ref-type="table"} presents the results of all the 39 serum biomarkers analyzed. The significant changes are in bold in [Table 2](#diagnostics-09-00212-t002){ref-type="table"} and the markers that remained significant after B--H correction are marked with an asterisk. At one-month follow-up, IL-8 in the placebo group and intact procollagen I N-terminal propeptide (iPINP) in the ZA group had decreased, whereas IP-10, MCP-1, SAA, and hs-CRP had increased in the ZA group ([Table 2](#diagnostics-09-00212-t002){ref-type="table"}, [Figures S1--S4](#app1-diagnostics-09-00212){ref-type="app"}). Compared to placebo, the decrease in biomarker concentration from baseline to one month was greater in the ZA group in terms of iPINP (median of change −9.3 vs. −0.7 ng/mL, *p* = 0.018) and in CTX-1 (−0.27 vs. −0.02 pg/mL, *p* = 0.009). At one month, there were no significant differences between the ZA and placebo groups after B--H correction.

At one-year follow-up, IL-16 in the placebo group, and Tie-2, AFOS and iPINP in the ZA group had decreased, whereas IP-10 and IFN-A had increased in the ZA group. During the one-year follow-up, one cytokine biomarker (IL-16) had decreased in the placebo group and two biomarkers (IP-10 and IFN-A) had increased in the ZA group. The change in IP-10 (decrease of --13.5 in the placebo group vs. increase of 61.1 pg/mL in the ZA group, *p* = 0.005) was significant after B--H correction. Two serum biomarkers (AFOS and iPINP) had not changed in the placebo group but had decreased in the ZA group (2.5 vs. −9.0 U/l, *p* \< 0.001 and 1.0 vs. −19.1 ng/mL, *p* \< 0.001; respectively). At one year, two biomarkers had significantly decreased in the ZA group after B--H correction: AFOS (71 to 57, *p* \< 0.001) and iPINP (36 to 15, *p* \< 0.001; [Table 2](#diagnostics-09-00212-t002){ref-type="table"}).

Among the patients with M2 at baseline, TARC had increased significantly during the one-year follow-up, whereas among the patients with M1 at baseline, AFOS and iPINP had decreased significantly ([Table S1](#app1-diagnostics-09-00212){ref-type="app"}). In the ZA group, the changes in total volume of MC and M1 volume during the one-year follow-up correlated positively with the changes in iPINP (Spearman's correlations (rho) 0.65 and 0.49). None of the other changes were significant and are presented in [Table S2](#app1-diagnostics-09-00212){ref-type="app"}. The changes in LBP intensity did not correlate statistically significantly with the changes in the concentration of any biomarker, as shown in [Table S3](#app1-diagnostics-09-00212){ref-type="app"}.

4. Discussion {#sec4-diagnostics-09-00212}
=============

In the present study, a single intravenous infusion of 5 mg ZA gave rise to different trends in the ZA and placebo groups, leading to significant differences at one-year follow-up in one chemokine (IP-10), which had increased in the ZA group and decreased in the placebo group, whereas two bone metabolism biomarkers (AFOS and iPINP) had decreased in the ZA group. Change in iPINP correlated with the change in the volume of all MC and M1 lesions.

We measured serum levels of AFOS, iPINP, and CTX-1 to evaluate bone formation and resorption. Of the bone biomarkers, iPINP decreased significantly at both one month and one year and AFOS at one year in the ZA group. The decreased concentrations in the bone biomarkers were not unexpected, as ZA has shown to suppress bone remodeling among post-menopausal women with osteoporosis \[[@B24-diagnostics-09-00212],[@B25-diagnostics-09-00212]\]. The former \[[@B24-diagnostics-09-00212]\] documented a 58% reduction in iPINP at one year after ZA administration among postmenopausal women with osteoporosis, whereas in the present study, iPINP concentration decreased by 19.4% at one month and 58.3% at one year, compared with 2.8% and 7.9% increases in the placebo group, respectively. A small French case-control study found no difference in bone mineral density and bone remodeling marker levels (serum C-terminal crosslinked type 1 telopeptide, procollagen type 1 N-terminal propeptide, osteocalcin and bone-specific alkaline phosphatase) among chronic LBP patients with M1 or without MC \[[@B20-diagnostics-09-00212]\].

In the chemokine panel, IP-10 was elevated at one month and at one year, while MCP-1 was elevated at one month in the ZA group. Both IP-10 and MCP-1 have been linked to pain \[[@B26-diagnostics-09-00212],[@B27-diagnostics-09-00212],[@B28-diagnostics-09-00212],[@B29-diagnostics-09-00212]\]. In animal models, ZA reduced the expression of a number of pro-inflammatory and angiogenic mediators, including MCP-1 \[[@B30-diagnostics-09-00212]\], whereas in our study, MCP-1 was elevated in the ZA group.

In the pro-inflammatory panel, IFN-A was elevated after one year in the ZA group---although not significantly so after B--H correction. Bisphosphonates do not only inhibit osteoclasts; they have also shown to suppress the secretion of proinflammatory cytokines such as IL-1, TNF-A, and IL-6 \[[@B31-diagnostics-09-00212]\]. Several studies have found upregulation of pro-inflammatory cytokines in endplates with MC \[[@B32-diagnostics-09-00212],[@B33-diagnostics-09-00212],[@B34-diagnostics-09-00212]\] and local anti-inflammatory treatment with glucocorticoid has shown to have a short-term alleviating effect on LBP \[[@B35-diagnostics-09-00212]\]. In our RCT, the improvement in LBP in the ZA group \[[@B21-diagnostics-09-00212]\] could have been due to the general ability of bisphosphonates to regulate bone turnover by suppressing osteoclast activity \[[@B36-diagnostics-09-00212]\] or to direct anti-inflammatory effects.

In the vascular injury panel, hs-CRP and SAA were elevated after one month in the ZA group (but not significantly after B--H correction), but at one year there was no difference. Some studies have shown that administration of bisphosphonates elevates the levels of circulating CRP, IL-6, TNF-A, and cortisol levels \[[@B37-diagnostics-09-00212],[@B38-diagnostics-09-00212]\]. ZA treatment often causes an acute phase reaction with fever and flu-like symptoms \[[@B39-diagnostics-09-00212]\]. The published studies of inflammation parameters in MC are based on tissue samples \[[@B32-diagnostics-09-00212],[@B40-diagnostics-09-00212],[@B41-diagnostics-09-00212]\], but only a few have assessed serum biomarkers. Rannou et al. found that high-sensitivity C-reactive protein (hsCRP) levels were elevated among patients with M1 and CLBP \[[@B19-diagnostics-09-00212]\]. An Australian study demonstrated that elevation of CRP and IL-6 during the acute phase of LBP was associated with better recovery, whereas individuals with elevated TNF had poorer prognoses \[[@B42-diagnostics-09-00212]\]. It might be that the "window of opportunity" to detect inflammatory serum biomarkers only exists in the early phase of MC development and shortly after the infusion of bisphosphonates.

A recent Dutch systematic review found moderate evidence of a positive association between the pro-inflammatory biomarkers CRP and IL-6 and the severity of nonspecific LBP, and a positive association between TNF-A and the presence of nonspecific LBP \[[@B43-diagnostics-09-00212]\]. If it were possible to determine a fingerprint in the serum of patients with LBP that is associated with MC, serum profiling could be used to assess the prognosis and choice of treatment. Khan et al. \[[@B44-diagnostics-09-00212]\] emphasized the potential of diagnostic biomarkers to guide an era of individualized spine medicine for personalized therapeutics in the treatment of LBP. In our study, however, the changes in LBP intensity did not correlate with the changes in any biomarker's concentration.

Because of their potent antiresorptive activity, bisphosphonates, including ZA, represent standards of care for the treatment of osteoporosis. Studies in vitro and in vivo have shown that, for example, pamidronate and clodronate inhibit the synthesis of proinflammatory cytokines \[[@B45-diagnostics-09-00212],[@B46-diagnostics-09-00212]\]. It has been proposed that the development of MC is dependent on the structural disruption of the intervertebral disc or endplate, and the inflammatory potential of the disc and the capacity of the bone marrow to respond to higher inflammatory stimuli \[[@B13-diagnostics-09-00212]\]. The source of pain is probably the chemical and mechanical stimulation of the nociceptors adjacent to the damaged endplates. It has also been suggested that a low virulent infection of anaerobic bacteria may induce edema and inflammation \[[@B47-diagnostics-09-00212]\]. When we exclude the theory of anaerobic infection from the pathophysiology of MC, we notice that ZA has several potential mechanisms for acting in MC lesions and is a promising, well-known and well-tolerated drug for treating LBP associated with MC. In the present study we could not prove the downregulation of serum biomarkers, including cytokines and growth factors, after ZA administration among LBP patients with MC. This might be due to our small sample size.

The strength of the present study is its randomized study design. Further strengths are its complete follow-up with no dropouts and 100% adherence, as medication was administered intravenously. All the analyses were performed using established, validated measurement assays in high-quality laboratories. Longitudinal data enable a better view of the possible inflammatory component in LBP with MC. However, we also acknowledge some limitations in our study. The small sample size of this pilot study might be inadequate to demonstrate significant changes in biomarkers, and multiple testing might increase the rate of false positive results. Thus, our results should be interpreted with caution. The possible presence of comorbidities and adverse lifestyles may affect the proinflammatory mediators observed in the systemic circulation of patients. For example, obesity is associated with increased serum levels of IL-6 and TNF-A \[[@B48-diagnostics-09-00212]\], and smoking is characterized by elevated serum levels of, for example, TNF-A and IL-1, as well as other cytokines \[[@B49-diagnostics-09-00212]\].

5. Conclusions {#sec5-diagnostics-09-00212}
==============

The present data demonstrated that a single intravenous infusion of 5 mg ZA gave rise to different trends in serum biomarkers in the ZA and placebo groups, leading to significantly different regulations at one-year follow-up for one chemokine (IP-10), whereas two bone metabolism biomarkers (AFOS and iPINP) decreased in the ZA group. ZA treatment had an expected downregulating effect on bone turnover markers. This study found an association, a positive correlation, between a change in iPINP concentration and the change in total volume of MC and M1 volume. The changes in LBP intensity did not correlate with the changes in any biomarker's concentration.

This is the first RCT to investigate ZA in MC and to observe how it is reflected in serum biomarkers. The evaluation of these biomarkers expands our understanding of the mechanism of MC and LBP and may thereby guide us to new diagnostic and therapeutic methods. It adds to our knowledge of the effects of ZA on MC and on the biomarkers signaling this process. We conclude that serum biomarkers can be used to monitor the treatment effect of ZA among LBP patients with MC. Larger studies are required to demonstrate the findings of this pilot study.

Supplementary materials can be found at [www.mdpi.com/link](www.mdpi.com/link).

###### 

Click here for additional data file.

Conceptualization, H.A., S.D., J.L., S.G., and J.K.; Methodology, J.R., M.-L.M., H.A., M.A., and S.G.; Software, M.H.; Validation, M.-L.M., J.R. and S.G.; Formal Analysis, M.H., S.G., K.K., and M.-L.M.; Investigation, J.J., O.T. and J.N.; Resources, E.K. and J.K.; Writing---Original Draft Preparation, K.K.; Writing---Review and Editing, K.K., J.K., J.L., S.D., D.S., S.G., M.A., J.R., M.-L.M., H.A., J.J., J.N. and O.T.; Visualization, M.H. and K.K.; Supervision, J.K. and E.K.; Project Administration, M.-L.M., S.G. and K.K.; Funding Acquisition, J.K., M.A., S.G. and E.K.

Novartis Pharma provided investigational medications for the study and supported the conduct of the trial (\<USD 10 000). The study was supported by the Hansjörg Wyss Research Award (AOSpine). The funders played no role in the study design, data collection or analysis, decision to publish, or in the preparation of the manuscript.

The authors declare no conflict of interest.

AFOS

alkaline phosphatase

bFGF

fibroblast growth factor beta

COMP

cartilage oligomeric matrix protein

CTX1

C telopeptide of type I collagen

Flt

fms related tyrosine kinase (=VEGFR1)

hs-CRP

high-sensitive C-reactive protein

HGF

hepatocyte growth factor

ICAM

intercellular adhesion molecule

IL

interleukin

IFN

interferon

IP

interferon-γ-inducible protein

iPINP

intact procollagen I N-terminal propeptide

LBP

low back pain

MC

Modic change

M1

type 1 Modic change

M2

type 2 Modic change

MCP

monocyte chemotactic protein

MDC,

macrophage derived chemokine

MIG

monokine induced by gamma-interferon

MIP

macrophage inflammatory protein

MRI

magnetic resonance imaging

ODI

Oswestry Disability Index

RANKL

receptor activator of NF-κB ligand

RANTES

regulated upon activation, normally T-expressed, and presumably secreted

SAA

serum amyloid A

SD

standard deviation

TARC

thymus and activation-regulated chemokine

Tie

TEK receptor tyrosine kinase

TNF

tumor necrosis factor

VAS

Visual Analog Scale

VCAM

vascular cell adhesion molecule

VEGF

vascular endothelial growth factor

ZA

zoledronic acid
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###### 

Characteristics of patients treated with zoledronic acid (ZA) and placebo. Group differences between age, body mass index (BMI), and Modic changes (MC) volumes were analyzed using the *t*-test. Otherwise, the chi-square test was used.

  Variable                               ZA              Placebo         *p*-Value
  -------------------------------------- --------------- --------------- -----------
  Age (years), mean (SD)                 49.2 (9.3)      51.5 (7.3)      0.400
  BMI (kg/m^2^), mean (SD)               26.1 (3.3)      27.4 (3.2)      0.203
  Males, *n* (%)                         15 (75.0%)      11 (55.0%)      0.320
  Regular smoker, *n* (%)                5 (25.0%)       6 (30.0%)       \>0.999
  **Primary MC type,** ***n*** **(%)**                                   0.103
    MI                                   3 (15.0%)       3 (15.0%)       
    MI/II-1                              14 (70.0%)      7 (35.0%)       
    MI/II-2                              2 (10.0%)       8 (40.0%)       
    MII                                  1 (5.0%)        2 (10.0%)       
  **Number of MCs, *n* (%)**                                             0.333
    1                                    10 (50.0%)      14 (70.0%)      
    2 or more                            10 (50%)        6 (30.0%)       
  **Volume of primary MC, mean (SD)**                                    
    Type 1                               7443 (4474)     5044 (3551)     0.068
    Type 2                               4542 (3897)     5868 (4840)     0.346
    Total                                11,985 (5140)   10,911 (5963)   0.546
  Osteoarthritis, *n* (%)                1 (5.0%)        6 (30.0%)       0.091
  Back pain (VAS), mean (SD)             6.6 (1.4)       6.8 (1.6)       0.646
  Leg pain (VAS), mean (SD)              3.0 (3.1)       2.9 (2.3)       0.864
  Oswestry disability index, mean (SD)   30.1 (11.0)     34.9 (9.8)      0.157

diagnostics-09-00212-t002_Table 2

###### 

Median concentrations and interquartile range (IQR) of serum biomarkers at baseline, one month and one year according to intervention (zoledronic acid (ZA) or placebo infusion). P^1^ shows the significance of the change in each respective biomarker concentration from baseline to one month or from baseline to one year. P^2^ shows the significance of the difference in change from baseline to one month or from baseline to one year in the concentration of each biomarker between the ZA and placebo groups. Significant *p*-values are in bold.

  Serum Biomarkers              Baseline Median (IQR)   1-Month Median (IQR)   P^1^        P^2^        1-Year Median (IQR)   P^1^          P^2^
  ----------------------------- ----------------------- ---------------------- ----------- ----------- --------------------- ------------- ----------------
  **Bone panel**                                                                                                                           
  AFOS (U/L)                                                                               0.554                                           **\<0.001 \***
  Placebo                       64 (53, 76)             63 (58, 77)            0.480                   61 (55, 82)           0.528         
  ZA                            71 (58, 80)             67 (62, 78)            0.826                   57 (49, 68)           **\<0.001**   
  RANKL (pg/mL)                                                                            0.369                                           0.724
  Placebo                       11.3 (0.0, 49.2)        14.6 (0.0, 67.2)       0.470                   11.3 (0.0, 59.6)      0.520         
  ZA                            13.0 (0.0, 37.0)        0.0 (0.0, 41.3)        0.891                   14.4 (0.0, 48.5)      0.853         
  iPINP (ng/mL)                                                                            **0.018**                                       **\<0.001 \***
  Placebo                       35 (27, 40)             36 (23, 42)            0.729                   38 (26, 45)           0.123         
  ZA                            36 (27, 49)             29 (20, 33)            **0.004**               15 (13, 18)           **\<0.001**   
  CTX-1 (pg/mL)                                                                            **0.009**                                       0.211
  Placebo                       0.2 (0.1, 0.4)          0.2 (0.1, 0.6)         0.546                   0.3 (0.2, 0.4)        0.189         
  ZA                            0.3 (0.2, 0.5)          0.0 (0.0, 0.0)         0.154                   0.2 (0.1, 5.4)        0.927         
  **Chemokine panel**                                                                                                                      
  Eotaxin-1 (pg/mL)                                                                        0.841                                           0.398
  Placebo                       214 (136, 263)          202 (151, 258)         0.956                   193 (149, 239)        0.622         
  ZA                            163 (146, 201)          167 (140, 224)         0.841                   180 (144, 232)        0.546         
  Eotaxin-3 (pg/mL)                                                                        0.565                                           0.862
  Placebo                       17.9 (10.5, 22.7)       16.0 (10.4, 19.6)      0.245                   13.9 (11.9, 19.9)     0.261         
  ZA                            20.2 (12.2, 31.6)       18.3 (11.5, 27.6)      0.076                   22.3 (12.9, 31.7)     0.388         
  IP-10 (pg/mL)                                                                            0.056                                           **0.005 \***
  Placebo                       265 (199, 349)          240 (204, 351)         0.756                   248 (171, 305)        0.177         
  ZA                            253 (187, 305)          282 (231, 423)         **0.036**               316 (240, 420)        **0.015**     
  MIP-1A (pg/mL)                                                                           0.518                                           0.817
  Placebo                       13.5 (5.3, 21.7)        16.7 (5.3, 21.5)       0.818                   16.7 (5.3, 19.1)      0.804         
  ZA                            5.3 (5.3, 16.3)         5.3 (5.3, 15.7)        0.945                   5.3 (5.3, 17.5)       0.719         
  MIP-1B (pg/mL)                                                                           0.883                                           0.091
  Placebo                       126 (79, 156)           102 (91, 161)          0.729                   106 (83, 158)         0.177         
  ZA                            85 (58, 144)            87 (63, 136)           0.330                   85 (66, 156)          0.277         
  MCP-1 (pg/mL)                                                                            0.327                                           0.174
  Placebo                       276 (226, 337)          286 (249, 332)         0.812                   267 (222, 346)        0.756         
  ZA                            237 (207, 281)          265 (207, 313)         **0.040**               279 (206, 326)        0.133         
  MCP-4 (pg/mL)                                                                            0.925                                           0.429
  Placebo                       158 (108, 189)          140 (111, 190)         0.674                   135 (109, 164)        0.701         
  ZA                            136 (105, 172)          133 (115, 180)         0.571                   136 (108, 193)        0.330         
  MDC-1 (ng/mL)                                                                            0.445                                           0.925
  Placebo                       1.1 (0.8, 1.4)          1.1 (0.8, 1.4)         0.498                   1.1 (0.7, 1.4)        0.546         
  ZA                            1.1 (0.9, 1.3)          1.0 (0.9, 1.2)         0.571                   1.0 (0.9, 1.2)        0.701         
  RANTES (ng/mL)                                                                           0.529                                           0.968
  Placebo                       78 (48, 168)            85 (52, 116)           0.245                   81 (62, 126)          0.261         
  ZA                            72 (50, 163)            80 (41, 126)           0.097                   81 (54, 113)          0.648         
  TARC (pg/mL)                                                                             0.157                                           0.512
  Placebo                       295 (197, 391)          326 (229, 438)         0.216                   329 (198, 411)        0.231         
  ZA                            202 (179, 391)          241 (169, 344)         0.409                   269 (161, 383)        0.812         
  MIG-1 (pg/mL)                                                                            0.908                                           0.122
  Placebo                       72 (65, 118)            72 (37, 154)           0.880                   72 (33, 118)          0.446         
  ZA                            69 (28, 132)            78 (33, 118)           0.939                   69 (47, 134)          0.262         
  **Cytokine panel**                                                                                                                       
  IL-7 (pg/mL)                                                                             0.738                                           0.445
  Placebo                       18.0 (14.0, 22.8)       15.8 (11.1, 20.9)      0.452                   14.4 (11.4, 17.7)     0.133         
  ZA                            19.3 (15.2, 23.7)       16.2 (13.9, 20.1)      0.154                   18.7 (13.9, 21.0)     0.064         
  IL-12/23p40 (pg/mL)                                                                      0.341                                           0.758
  Placebo                       122 (92, 157)           113 (87, 185)          0.571                   116 (94, 154)         0.898         
  ZA                            102 (77, 145)           97 (84, 134)           0.546                   100 (84, 135)         \>0.999       
  IL-15 (pg/mL)                                                                            0.134                                           0.678
  Placebo                       2.8 (2.3, 3.4)          2.6 (2.4, 3.3)         0.985                   2.8 (2.5, 3.2)        0.869         
  ZA                            3.0 (2.5, 3.2)          3.1 (2.6, 3.4)         0.123                   3.0 (2.7, 3.3)        0.312         
  IL-16 (pg/mL)                                                                            0.301                                           **0.035**
  Placebo                       191 (151, 246)          194 (167, 213)         0.515                   172 (156, 200)        **0.027**     
  ZA                            173 (151, 223)          205 (174, 220)         0.349                   207 (167, 248)        0.245         
  IL-17A (pg/mL)                                                                           0.201                                           0.841
  Placebo                       2.3 (1.7, 3.3)          2.6 (1.5, 3.3)         0.177                   2.6 (1.5, 3.5)        0.869         
  ZA                            2.2 (1.5, 3.3)          2.3 (1.6, 2.9)         0.622                   2.2 (1.4, 3.4)        0.829         
  TNF-B (pg/mL)                                                                            0.175                                           0.636
  Placebo                       0.4 (0.1, 0.5)          0.4 (0.1, 0.5)         0.761                   0.3 (0.1, 0.5)        0.940         
  ZA                            0.1 (0.1, 0.4)          0.1 (0.1, 0.4)         0.240                   0.3 (0.1, 0.4)        0.588         
  **Anti-inflammatory panel**                                                                                                              
  IL-1sRII (ng/mL)                                                                         0.989                                           0.391
  Placebo                       22.1 (18.8, 28.1)       23 (15, 26)            0.515                   23 (16, 27)           0.651         
  ZA                            24.7 (20.5, 28.0)       22 (19, 28)            0.522                   25 (21, 27)           0.181         
  **Pro-inflammatory panel**                                                                                                               
  IFN-A (pg/mL)                                                                            0.329                                           0.267
  Placebo                       71 (55, 91)             66 (47, 87)            0.806                   66 (55, 95)           0.924         
  ZA                            61 (55, 78)             66 (55, 78)            0.070                   71 (58, 79)           **0.032**     
  IFN-G (pg/mL)                                                                            0.820                                           0.445
  Placebo                       5.6 (4.3, 9.3)          4.7 (3.2, 9.6)         0.498                   4.6 (3.7, 8.0)        0.245         
  ZA                            4.5 (3.3, 7.1)          5.5 (3.2, 8.8)         0.898                   5.3 (3.1, 8.3)        0.756         
  IL-2R (pg/mL)                                                                            0.425                                           0.625
  Placebo                       144 (95, 229)           164 (109, 214)         0.225                   123 (89, 193)         0.671         
  ZA                            117 (97, 163)           117 (90, 161)          0.588                   125 (97, 150)         0.899         
  IL-6 (pg/mL)                                                                             0.445                                           0.192
  Placebo                       0.8 (0.5, 1.1)          0.6 (0.5, 1.1)         0.648                   0.7 (0.4, 0.8)        0.105         
  ZA                            0.7 (0.4, 0.9)          0.6 (0.5, 1.0)         0.674                   0.6 (0.5, 0.9)        0.522         
  IL-8 (pg/mL)                                                                             0.583                                           0.659
  Placebo                       11.1 (7.5, 14.9)        10.2 (7.9, 11.6)       **0.040**               9.2 (6.8, 12.2)       0.165         
  ZA                            9.7 (7.5, 11.7)         9.7 (7.4, 14.2)        0.294                   10.0 (7.6, 13.7)      0.546         
  TNF-A (pg/mL)                                                                            0.512                                           **0.049**
  Placebo                       2.0 (1.6, 2.3)          2.0 (1.7, 2.2)         0.231                   1.8 (1.4, 2.2)        0.294         
  ZA                            1.6 (1.2, 2.2)          1.7 (1.3, 2.3)         0.956                   1.7 (1.2, 2.5)        0.202         
  **Angiogenesis panel**                                                                                                                   
  VEGF-A (pg/mL)                                                                           0.758                                           0.947
  Placebo                       249 (110, 388)          198 (125, 320)         0.596                   182 (111, 406)        0.729         
  ZA                            380 (167, 530)          348 (178, 502)         0.189                   412 (170, 497)        0.841         
  VEGF-C (pg/mL)                                                                           0.947                                           0.369
  Placebo                       417 (342, 498)          459 (288, 510)         0.812                   432 (330, 548)        0.245         
  ZA                            392 (382, 506)          399 (369, 501)         0.596                   403 (346, 514)        0.869         
  VEGF-D (ng/mL)                                                                           0.529                                           0.495
  Placebo                       0.7 (0.6, 1.0)          0.8 (0.6, 1.0)         0.349                   0.8 (0.6, 0.9)        0.105         
  ZA                            0.7 (0.6, 0.9)          0.7 (0.6, 0.8)         0.596                   0.7 (0.6, 0.9)        0.571         
  Tie-2 (ng/mL)                                                                            0.529                                           0.314
  Placebo                       4.6 (4.0, 5.2)          4.7 (3.7, 5.5)         0.869                   4.5 (3.9, 5.1)        0.701         
  ZA                            4.4 (4.0, 5.3)          4.4 (3.7, 5.1)         0.245                   4.3 (3.5, 4.9)        **0.019**     
  Flt-1 (pg/mL)                                                                            0.925                                           0.989
  Placebo                       88 (77, 97)             91 (63, 126)           0.812                   90 (80, 99)           0.756         
  ZA                            91 (75, 98)             83 (76, 93)            0.349                   82 (78, 99)           0.756         
  bFGF (pg/mL)                                                                             0.659                                           0.659
  Placebo                       3.4 (1.9, 5.1)          3.2 (2.3, 5.3)         0.869                   3.5 (1.9, 8.0)        0.123         
  ZA                            5.2 (2.7, 7.3)          3.7 (2.9, 7.1)         0.522                   4.5 (3.8, 8.3)        0.522         
  HGF-1 (pg/mL)                                                                            0.974                                           0.201
  Placebo                       205 (110, 263)          184 (115, 248)         0.874                   157 (84, 248)         0.245         
  ZA                            146 (89, 219)           143 (67, 193)          0.374                   171 (89, 248)         0.430         
  **Vascular injury panel**                                                                                                                
  hs-CRP (mg/L)                                                                            0.176                                           0.551
  Placebo                       1.2 (0.4, 2.6)          0.9 (0.6, 1.9)         0.936                   0.9 (0.6, 2.0)        0.157         
  ZA                            0.9 (0.5, 1.2)          1.3 (0.4, 2.2)         **0.042**               0.8 (0.4, 1.3)        0.652         
  ICAM-1 (µg/mL)                                                                           0.341                                           0.773
  Placebo                       0.4 (0.4, 0.5)          0.4 (0.3, 0.5)         0.368                   0.4 (0.3, 0.5)        0.196         
  ZA                            0.4 (0.3, 0.5)          0.4 (0.3, 0.5)         0.622                   0.3 (0.3, 0.4)        0.073         
  VCAM-1 (µg/mL)                                                                           0.547                                           0.603
  Placebo                       0.6 (0.6, 0.8)          0.6 (0.5, 0.7)         0.409                   0.6 (0.5, 0.7)        0.096         
  ZA                            0.6 (0.5, 0.7)          0.5 (0.5, 0.7)         0.841                   0.5 (0.5, 0.7)        0.369         
  SAA (µg/mL)                                                                              0.512                                           0.954
  Placebo                       1.8 (1.1, 4.1)          1.9 (1.2, 4.2)         0.452                   1.7 (1.3, 2.5)        0.595         
  ZA                            1.7 (0.8, 2.2)          1.9 (1.0, 4.3)         **0.048**               1.5 (0.6, 2.8)        0.922         

^1^ Significance in Wilcoxon signed rank test, ^2^ Significance in Mann--Whitney's test; \* significant after B--H correction; AFOS = alkaline phosphatase; bFGF = basic fibroblast growth factor beta; CTX1 = C telopeptide of type I collagen; Flt = fms related tyrosine kinase (=VEGFR1); HGF = hepatocyte growth factor; hs-CRP = high-sensitive C-reactive protein; ICAM = intercellular adhesion molecule; IL = interleukin; IFN = interferon; IP = interferon-γ-inducible protein; iPINP = intact procollagen I N-terminal propeptide; MCP = monocyte chemotactic protein; MDC = macrophage derived chemokine; MIG = monokine induced by gamma-interferon; MIP = macrophage inflammatory protein; RANKL = receptor activator of NF-κB ligand; RANTES = regulated upon activation, normally T-expressed, and presumably secreted; SAA = serum amyloid A; TARC = thymus and activation-regulated chemokine; Tie = TEK receptor tyrosine kinase; TNF = tumor necrosis factor; VCAM = vascular cell adhesion molecule; VEGF = vascular endothelial growth factor.
